Sign in

CIK 0001642380

  • Non-accelerated filer
  • Smaller reporting company

Insight Molecular Diagnostics Inc.

Sign in to watch
Ticker
IMDX
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
CA
Entity type
Operating
EIN
271041563
Phone
+1 949-409-7600
Business address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, TN, 37217
Former names
OncoCyte Corp, Oncocyte Corp
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 23 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-03-26 Riggs Josh CEO and President Option exercise +47,170 50,675
2026-03-26 Riggs Josh CEO and President Shares withheld for taxes −12,310 $4.11 $51K 38,365
2026-03-26 Riggs Josh CEO and President Option exercise · Restricted Stock Units −47,170 141,509
2025-09-28 Riggs Josh CEO and President Grant or award · Option to Purchase Common Stock +400,000 400,000
2025-03-26 Riggs Josh CEO and President Grant or award · Restricted Stock Units +188,679 188,679
2024-05-20 Riggs Josh CEO and President Grant or award · Option to Purchase Common Stock +90,000 90,000
2024-04-11 Riggs Josh CEO and President Purchase +3,390 $2.95 $10K 3,505
2023-08-15 Riggs Josh CEO and President Grant or award · Option to Purchase Common Stock +40,000 40,000
2023-06-09 Riggs Josh CEO and President Grant or award · Option to Purchase Common Stock +350,000 350,000
2023-06-09 Riggs Josh CEO and President Grant or award · Option to Purchase Common Stock +800,000 800,000
2023-02-24 Riggs Josh CEO Grant or award · Option to Purchase Common Stock +116,426 116,426
2023-01-17 Riggs Josh Interim CEO Grant or award · Option to Purchase Common Stock +257,485 257,485

Page 1 of 1 · 12 trades